Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06857708 · ClinicalTrials.gov registry record · NA
The Management of Necrotizing Soft Tissue Infection Wounds With Cytal® Wound Matrix and MicroMatrix®
A NA study of Necrotizing Soft Tissue Infection and Necrotizing Fascitis, sponsored by Benjamin T. Miller.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06857708: Recruiting NA study of Necrotizing Soft Tissue Infection and Necrotizing Fascitis, sponsored by Benjamin T. Miller.
NCT06857708 is a NA study of Necrotizing Soft Tissue Infection and Necrotizing Fascitis that is actively recruiting participants, run by Benjamin T. Miller. The registered enrollment target is 50 participants, below the 331-participant average among 3 other Necrotizing Soft Tissue Infection trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06857708, a NA study of Necrotizing Soft Tissue Infection and Necrotizing Fascitis, is actively recruiting participants, sponsored by Benjamin T. Miller.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, pilot, parallel group, randomized controlled trial with 1:1 allocation. This will be a single center study coordinated at the Cleveland Clinic Foundation (CCF) Main Campus in Cleveland, Ohio. Data will be collected in a secure manner using REDCap housed at CCF. The study will consist of 2 arms: treatment with Cytal® Wound Matrix 2-Layer and MicroMatrix® (Integra LifeSciences, Plainsboro Township, NJ, U.S.A.) versus standard of care dressings. Wound debridement procedures will be performed by surgical staff at CCF. A co-investigator trained in the application of Cytal® Wound Matrix and MicroMatrix® will apply these treatments as outlined in section 6.1.2 Administration. This study will be conducted with IRB approval and written informed consent of each participant enrolled. The trial will be registered at ClinicalTrials.gov before the first participant is enrolled.
Conditions Studied
Interventions
- DEVICE Cytal® Wound Matrix
- DEVICE MicroMatrix®
Study Locations (1)
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-03-05 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT06857708 shows while recruiting
NCT06857708 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 331-participant average among 3 other Necrotizing Soft Tissue Infection trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with Necrotizing Soft Tissue Infection appearing as the primary indexed condition, and to 2 interventions - of which Cytal® Wound Matrix is the first listed.
NCT06857708 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06857708 about?
NCT06857708 is a clinical study titled "The Management of Necrotizing Soft Tissue Infection Wounds With Cytal® Wound Matrix and MicroMatrix®". This is a prospective, pilot, parallel group, randomized controlled trial with 1:1 allocation. This will be a single center study coordinated at the Cleveland Clinic Foundation (CCF) Main Campus in Cleveland, Ohio. Data will be collected in a secure manner using REDCap housed at CCF. The study will ...
What is the current status of trial NCT06857708?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2025-03-05. Estimated completion is 2026-12-31.
What conditions does trial NCT06857708 study?
This clinical trial studies the following conditions: Necrotizing Soft Tissue Infection, Necrotizing Fascitis.
What interventions are being tested in trial NCT06857708?
The interventions under investigation include: Cytal® Wound Matrix (DEVICE), MicroMatrix® (DEVICE).
Who is sponsoring clinical trial NCT06857708?
This trial is sponsored by Benjamin T. Miller, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06857708 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Necrotizing Soft Tissue Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI